Drug Trial Radar · NCT01431300
Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Dec 10, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Aug 2011
Primary completion
Jul 2012
Study completion Jul 2013
Sponsor
- Lead sponsor
- Duke UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Lantheus Medical Imaging
- First posted
- Sep 9, 2011
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram (MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar. Quantitative and qualitative analysis will be performed on the images.
Conditions
- Healthy
Interventions
gadofosvesetDrug
Intravenous administration of the specified dosage of gadolinium contrast agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Imaging Quality ScoreTime frame: 14 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Duke University Medical Center
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.